MedTrace Logo

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

NCT00323869 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-09-07

Study results available
· View outcomes & findings →

Summary

A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

Bevacizumab

Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody

DRUG

Gemcitabine

Nucleoside analog

DRUG

Carboplatin

Alkylating agent

Sponsors & Collaborators

Principal Investigators

  • Heather A Wakelee, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00323869 on ClinicalTrials.gov